(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.

Saved in:
Bibliographic Details
Main Authors CASTRO PALOMINO LARIA, Julio Cesar, VALLS VIDAL, Nuria, ORTEGA MUÑOZ, Alberto, FYFE, Matthew Colin Thor, MARTINELL PEDEMONTE, Marc, ESTIARTE MARTÍNEZ, María de los Ángeles, KURZ, Guido
Format Patent
LanguageEnglish
French
German
Published 26.12.2018
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
AbstractList The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
Author ORTEGA MUÑOZ, Alberto
CASTRO PALOMINO LARIA, Julio Cesar
KURZ, Guido
VALLS VIDAL, Nuria
ESTIARTE MARTÍNEZ, María de los Ángeles
FYFE, Matthew Colin Thor
MARTINELL PEDEMONTE, Marc
Author_xml – fullname: CASTRO PALOMINO LARIA, Julio Cesar
– fullname: VALLS VIDAL, Nuria
– fullname: ORTEGA MUÑOZ, Alberto
– fullname: FYFE, Matthew Colin Thor
– fullname: MARTINELL PEDEMONTE, Marc
– fullname: ESTIARTE MARTÍNEZ, María de los Ángeles
– fullname: KURZ, Guido
BookMark eNrjYmDJy89L5WSw0vBwDXEN8td0DIr0UXCOdPbxDwjyD4j0cfT19HNVcPb3DfAP9XMJVnAMVvAJdjFU8PTz8HTyDPEPCuZhYE1LzClO5YXS3AwKbq4hzh66qQX58anFBYnJqXmpJfGuAUbm5mbGliZOhsZEKAEAhH4qqg
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate COMPOSÉS D'(HÉTÉRO)ARYL-CYCLOPROPYLAMINE À TITRE D'INHIBITEURS DE LSD1
(HETERO-)ARYLCYCLOPROPYLAMINVERBINDUNGEN ALS LSD1-INHIBITOREN
ExternalDocumentID EP2776394B1
GroupedDBID EVB
ID FETCH-epo_espacenet_EP2776394B13
IEDL.DBID EVB
IngestDate Fri Jul 19 12:46:52 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
German
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_EP2776394B13
Notes Application Number: EP20120787388
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181226&DB=EPODOC&CC=EP&NR=2776394B1
ParticipantIDs epo_espacenet_EP2776394B1
PublicationCentury 2000
PublicationDate 20181226
PublicationDateYYYYMMDD 2018-12-26
PublicationDate_xml – month: 12
  year: 2018
  text: 20181226
  day: 26
PublicationDecade 2010
PublicationYear 2018
RelatedCompanies Oryzon Genomics, S.A
RelatedCompanies_xml – name: Oryzon Genomics, S.A
Score 3.1833355
Snippet The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their...
SourceID epo
SourceType Open Access Repository
SubjectTerms ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title (HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20181226&DB=EPODOC&locale=&CC=EP&NR=2776394B1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3fS8MwED7GFPVNp-LmD_IgRR-KW9tlThiyph2ttE1pN9meRpt2sJduuIr_vpeyTV_0LSRwXA6-fHfJ3QXg3uhriZbrVEUqxgAlFbqapoKqVIgsN9oJzRIZKPoBdSbG27Q7rcFyVwtT9Qn9qpojIqIE4r2szuv1zyWWVeVWbp7SJU6tXkfjgaVso2NJVxpVLHNgh9ziTGEMR0oQDbQeAqlvmBgoHaAX3ZNgsN9NWZSy_s0oo1M4DFFYUZ5BLS8acMx2H6814MjfvnfjcAu9zTm8PDg2up78cRjNPMJmzONhxMOZN_TdwCaM-yGfBFZMhjHxYqtD3MBxTXfMo_gCyMgeM0dFJeb7Dc_tcK-ufgn1YlXkV0CekUho3mmLbEENStNE13Sju-hnQuKqS5vQ_FNM65-1aziRlpM5Ghq9gXr58ZnfItOW6V1lo29JSX0m
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsX5mQcp-lDc2i5zwpA17Wi1bUrbyfY0-jXYSzdcxX_fS9mmL_oWEjguB7_87pK7C8Cd1ldiJVepjFSMAUqSqnKSpFSmaZrlWjumWSwCRdej1lh7nXQnNVhsa2GqPqFfVXNERFSKeC-r83r1c4llVLmV68dkgVPLl1E0MKRNdCzoSqGSoQ9MnxucSYzhSPKCgdJDIPU1HQOlPfSwewIM5rsuilJWvxlldAT7PgorymOo5UUTGmz78VoTDtzNezcON9Bbn8DzvWWi68kfhsHUIWzKHO4H3J86Q9f2TMK46_OxZ4RkGBInNDrE9ixbtyMehKdARmbELBmVmO02PDP9nbrqGdSLZZGfA3lCIqF5p51mc6pRmsSqomrdeT9LBa66tAWtP8Vc_LN2Cw0rcp2ZY3tvl3AorCjyNRR6BfXy4zO_RtYtk5vKXt9S9YAZ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=%28HETERO%29ARYL+CYCLOPROPYLAMINE+COMPOUNDS+AS+LSD1+INHIBITORS&rft.inventor=CASTRO+PALOMINO+LARIA%2C+Julio+Cesar&rft.inventor=VALLS+VIDAL%2C+Nuria&rft.inventor=ORTEGA+MU%C3%91OZ%2C+Alberto&rft.inventor=FYFE%2C+Matthew+Colin+Thor&rft.inventor=MARTINELL+PEDEMONTE%2C+Marc&rft.inventor=ESTIARTE+MART%C3%8DNEZ%2C+Mar%C3%ADa+de+los+%C3%81ngeles&rft.inventor=KURZ%2C+Guido&rft.date=2018-12-26&rft.externalDBID=B1&rft.externalDocID=EP2776394B1